Loading stock data…
$1.56+0.03 (+1.96%)
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States.
InflaRx N.V. in the Healthcare sector is trading at $1.56 with a market capitalization of $298M. Wall Street consensus targets $8.27 (8 analysts), implying a +430.4% move over the next 12 months. The stock is currently 47% below its 52-week high of $2.95, remaining 3.7% below its 200-day moving average. On fundamentals, Piotroski 1/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 45/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0↑ | -$33,931↓ | $23,830↓ | $39,432 |
| Gross Profit | $0 | $0↑ | -$4.89M↓ | $23,497↑ | -$2.36M |
| Operating Income | -$7.00M↑ | -$7.21M↑ | -$12.86M↓ | -$9.48M↑ | -$12.94M |
| Net Income | -$10.65M↓ | -$5.59M↑ | -$10.64M↑ | -$12.26M↑ | -$14.42M |
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator to treat variety of autoimmune and other inflammatory dis...